• Neuromuscular disorders and skeletal myopathies comprise a very heterogeneous and somewhat rare group of disorders that often involves multiple organs and have overlapping clinical manifestations.
• The molecular genetic basis of many neuromuscular disorders and skeletal myopathies have been delineated during the past two decades, providing insight into the pathogenesis of these disorders and raising the possibility of preclinical diagnosis, risk stratifi cation, and specifi c therapies.
• The heart is commonly involved in neuromuscular disorders and skeletal myopathies.
• Cardiac involvement is often subclinical. Hence, routine systematic cardiac evaluation is warranted in all patients with neuromuscular disorders and skeletal myopathies.
• Cardiac involvement typically manifests as dilated cardiomyopathy with congestive heart failure.
• Cardiac conduction defects involving sinoatrial (SA) and atrioventricular (AV) nodes and bundle branches are common and progressive, particularly in neuromuscular disorders such as myotonic dystrophy and muscular dystrophies, often requiring permanent pacemaker implantation.
• Cardiac hypertrophy is present in a signifi cant number of patients with neuromuscular disorders, such as Friedreich ataxia and often mimics hypertrophic cardiomyopathy (phenocopy).
• Cardiac involvement is the major cause of morbidity and mortality in patients with neuromuscular disorders and skeletal myopathies.
The heart is commonly involved in skeletal myopathies and neuromuscular disorders, particularly in primary disorders caused by genetic mutations. Cardiac involvement usually manifests as cardiomyopathy, as dilated (DCM) or hypertrophic (HCM) cardiomyopathy, and less commonly, as cardiac arrhythmias and conduction defects. Cardiac involvement could be the fi rst manifestations of the disease and often is indicative of a poor prognosis. Indeed, cardiac involvement is a major cause of morbidity and mortality in patients with skeletal myopathies or neuromuscular disorders. Accordingly, periodic assessment of cardiovascular system in such patients is necessary. Routine and periodic cardiac evaluation could lead to early detection and appropriate management of cardiac disease. The initial evaluation should include a careful history and physical examination, 12-lead electrocardiography (ECG), two-dimensional (2D) and Doppler echocardiography, and measurements of serum levels of creatine kinase and myoglobin. Additional cardiac investigation is warranted as deemed necessary according to clinical presentation and known natural history of the disease. The list of skeletal myopathies and neuromuscular disorders that involve the heart is extensive and practically inclusive of the vast majority of such disorders. However, the prevalence of cardiac involvement varies and is common only in a fraction of skeletal and neuromuscular disorders. [1] [2] [3] [4] [5] Table 112 .1 is an abbreviated list of the genetic myopathies and neuromuscular disorders in which cardiac involvement is a signifi cant part of the phenotype. Several of these disorders are discussed here. 
Phenotypic Defi nition
Duchenne/Becker muscular dystrophy (DMD/BMD) is a primary skeletal myopathy characterized by progressive degeneration and contraction of the proximal muscles. 6 It is commonly associated with pseudohypertrophy of the calves. Duchenne muscular dystrophy, BMD, and X-linked DCM are phenotypic variants. Duchenne is the most common form and represents the severe form and Becker is a milder form of the disease, while in X-linked DCM the phenotype is restricted to the heart. 3, [6] [7] [8] 
Molecular Genetics
Duchenne/Becker muscular dystrophy is an X-linked recessive disorder caused by mutations in dystrophin (DMD) on the Xp2l locus. DMD spans approximately 2.4 million base pairs (bp) of DNA and is composed of 79 exons, which encode a 14-kbp messenger RNA (mRNA) and a 500-kd protein. 9 Dystrophin, among the largest known proteins in the striated muscles, is a rod-shaped protein with two globular heads that links the cytoplasmic actin fi laments and the complex of dystrophin-associated glycoproteins ( Fig. 112.1) . 10, 11 The N-terminal domain of dystrophin contains a calponin-like actin-binding domain, which is responsible for anchoring dystrophin to cytoskeletal fi lamentous actin. 12 The central rod domain of dystrophin consists of 24 spectrin-like repeats, which provide structural stiffness and has a second site binding to γ-actin between pectrin repeats 11 through 17. The C-terminal domain is a cysteine-rich region, which interacts with the intracellular portion of the transmembrane protein β-dystroglycan and anchors dystrophin to the sarcolemma. In addition, the α-helical portion of the N-terminal domain also interacts with the syntrophins. Hence, dystrophin is considered a component of mechanical stabilization of the skeletal and cardiac myocytes. 10 Almost all cases of DMP/BMD are caused by mutations in DMD. 3, 13 More than 60% of DMD and BMD mutations are deletion mutations, predominantly involving exons in the 5-prime and central portions of the gene, which have been referred to as the minor and major deletion hot spots, respectively. 13, 14 Deletion mutations lead to the premature truncation of the protein that is defective in incorporation into the sarcolemmal membrane in the skeletal and cardiac muscles. Thus, dystrophin is absent from the sarcolemmal membranes of skeletal and cardiac muscle in the affected individuals. Quantitative assays for dystrophin and skeletal muscle biopsies can identify female carriers of the genetic defect; this permits more accurate genetic counseling and may assist in perinatal diagnosis of DMD.
Clinical Manifestations
Edward Meryon, an English physician, was the fi rst to describe clinical and pathologic features of DMD, including disruption of muscle sarcolemma in 1852. 15 French neurologist Duchenne described the disease as "hypertrophic paraplegia of infancy" in 1861. 15 The estimated incidence of DMD is approximately 1 in 5000 male live births and that of BMD is approximately one fi fth as much. 16 Duchenne/Becker muscular dystrophy are X-linked disorders and hence predominantly affect males. Female carriers are commonly spared but could exhibit a mild phenotype that manifests late in life. 17 Duchenne/Becker muscular dystrophy is characterized by progressive degeneration of skeletal and cardiac muscle functions, typically involving the proximal skeletal muscles, which leads to the characteristic phenotype of pseudohypertrophy of the calve muscles. 6, 15, 18 Duchenne muscular dystrophy usually manifests during the fi rst few years of life and is rapidly progressive, leading to premature death during the second and third decades, commonly from respiratory and cardiac failure. In contrast, the clinical manifestations of BMD start in the second and third decades of life and the disease progresses gradually over the next couple of decades. Pseudohypertrophy, which is the replacement of normal muscle by fat and connective tissue, occurs in the gastrocnemius muscles, giving the classic appearance of disproportionately enlarged calve muscles. By the age of 7 to 8 years, contractures of the Achilles tendon and the iliotibial bands result in toe walking and lordotic posture, respectively. The muscle weakness progresses, with a predilection for the neck and proximal limb muscles, resulting in a fl oppy, unsupported head. As the contractures progress, the affected individuals suffer from severe scoliosis and become confi ned to wheelchair (Fig. 112.2 ). Respiratory function becomes compromised owing to muscle weakness and chest cage deformities. The average life span is about 20 years, with cardiac failure and respiratory insuffi ciency being the most common causes of death. Pulmonary infection is often the precipitating factor for death from respiratory and cardiac failure.
Cardiac Involvement
Duchenne/Becker muscular dystrophy is the prototypic skeletal myopathy, in which cardiac involvement is a major component of the phenotype and an important determinant of morbidity and mortality. 6 Cardiac involvement is very common and often manifests during the fi rst decade of life in DMD and later in BMD, or may be present in the absence of skeletal myopathy. 19, 20 Routine cardiac evaluation of patients with DMD/BMD should include ECG, Holter monitoring, echocardiography, and chest x-ray every 6 months. Once cardiac involvement is detected, the above examinations should be performed every 3 months to monitor the patient closely.
Cardiac manifestations in DMD/BMD could include involvements of the conduction system, myocardium, and valves. Electrocardiographic abnormalities are quite common, could be present in the affected individuals within the fi rst few years of life, and are present in approximately half of patients in the second decade of life. [21] [22] [23] Progressive atrioventricular block, loss of P-wave amplitude, atrial standstill, and ventricular arrhythmia are the common fi ndings. Table  112 .2 lists the common electrocardiographic abnormalities detected in patients with DMD/BMD. A representative ECG is shown in Figure 112 .3. These electrocardiographic abnormalities can be explained by the marked focal interstitial and replacement fi brosis that specifi cally involves the posterobasal wall of the left ventricle and the posterior papillary muscle. The pathologic Q waves are typically deep and narrow (rarely >0.04 second) and are distinguishable from the Q waves of myocardial infarction, which are usually shallow and broad. Unique patterns of electrocardiographic abnormalities occur frequently in families. Type 1 consists of tall R waves in V 1 and deep Q waves in V 4 and V 6 . Type 2 consists of rSR and deep Q waves in V 5 through V 6 . This may represent subtle variations in pathology that result from different familial genetic mutations. The dysrhythmias associated with DMD/BMD are inappropriate sinus tachycardia, atrial fl utter, premature atrial and ventricular beats, complete heart block, and, rarely, a shifting pacemaker from the sinoatrial (SA) node to the atrioventricular (AV) node. Ventricular dysrhythmias are uncommon, but, along with left ventricular dysfunction, are the major causes of sudden cardiac death (SCD).
Involvement of myocardium manifests as akinesis or dyskinesis of the posterobasal wall of the left ventricle and cardiomyopathies. 24 Cardiac involvement in Duchenne muscular dystrophy is more common and often the primary feature of DMD/BMD and a major predictor of mortality ( Fig.  112.4) . 22 Cardiac function deteriorates with age and detectable cardiac function abnormalities are present in virtually every affected individual older than 18 years. Most patients with cardiomyopathies do not demonstrate clinical symptoms of heart failure due to a very slow evolution of the cardiomyopathy, allowing the development of more complete compensatory mechanisms. In addition, reduced cardiac demand in these relatively immobile patients masks the clinical manifestations of cardiomyopathies. Nevertheless, approximately 90% of patients eventually develop DCM 3 and death often occurs by the third decade of life. 3, 22 Other notable fi ndings in cardiac evaluation of patients with DMD/BMD include mitral valve prolapse; myocardial perfusion defect involving the posterobasal free wall of the left ventricle, which correlates with the localized fi brosis in this region; increased 18 F-2-fl uorodeoxyglucose; decreased 13 NH 3 uptake in the posterobasal left ventricular (LV) free wall on positron emission tomography; and abnormal myocardial energetics. 20, 25, 26 Overall, there is no specifi c therapy for the treatment of DMD/BMD, and the current management approach is based largely on treatment of symptoms and prevention of complications, such as respiratory infection. Treatment of cardiac complications follows the standard approaches, such as the use of beta-blockers and angiotensin-1-converting enzyme blockers in the treatment of congestive heart failure (CHF) and implantation of permanent pacemakers for those with advanced conduction defects. An important issue is early detection of cardiac involvement, since many individuals are asymptomatic in early stages of the disease and hence are undetected. Routine screening of all cases with muscular dystrophy to detect early and preclinical cardiac involvement is warranted. Careful and frequent monitoring and treatment following the diagnosis of cardiac involvement could slow the progression of disease. Since DCM could occur in the absence of skeletal myopathy, cardiac transplantation could prove benefi cial.
A number of experimental approaches to the treatment of patients with DMD/BMD have been attempted with considerable success in experimental models, including use of growth hormone, 27 overexpression of utrophin, 28 myoblast transfer into skeletal and cardiac muscles, 29 antisense DNA, Tall R wave with high R/S ratio in V 1 Very common
Deep narrow Q wave >4 mm in I, aVL, V 5 , V 6 Very common
Sinus tachycardia Very common
Right-axis deviation Uncommon
Short PR interval Uncommon
Fascicular blocks Common
Complete heart blocks Uncommon gene therapy through expression of mini-or microdystrophin proteins, 31, 32 and use of aminoglycosides to read through the stop codons. 33 Potential utility of these approaches in humans is subject to vigorous investigations. 34 Emery-Dreifuss Syndrome (OMIM Number 310300)
Phenotypic Defi nition
The classic Emery-Dreifuss muscular dystrophy (EDMD) is an X-linked disorder characterized by progressive degeneration and atrophy of skeletal muscles, and contractures at the neck, elbows, and Achilles tendons. 6, 35 Autosomal dominant and recessive forms of EDMD also have been described, which are considered allelic variants of limb-girdle muscular dystrophy. 6 
Molecular Genetics
The classic EDMD is caused by mutations in Emerin (EMD), which has been mapped to Xq28. 36 Emerin is an inner nuclear envelope protein that is expressed in many cell types including cardiac and skeletal myocytes. Emerin is involved in membrane anchorage to the cytoskeleton. The hydrophobic C-terminal domain of emerin is associated with the intercalated disks in the heart and skeletal muscles. Mutations in emerin result in defi ciency of this protein in the heart and skeletal muscles. 37 Autosomal dominant and recessive forms of EDMD are caused by mutations in lamin A/C (LMNA), located on 1q21.2. 36 Autosomal dominant EDMD is considered an allelic variant of limb-girdle muscular dystrophy type 1B (both are caused by mutations in LMNA).
Clinical Manifestations
Emery-Dreifuss muscular dystrophy is a rare disorder that was originally described by Dreifuss and Hope in 1961 and subsequently was fully characterized, including a description of the cardiac symptoms, by Emery and Dreifuss in 1966. 38, 39 The classic triad described comprises early contractures of the elbows, posterior cervical muscles, and Achilles tendons; slowly progressive muscle wasting and weakness in a humeroperoneal distribution; and cardiomyopathy and cardiac conduction abnormalities. Overall, the classic EDMD is characterized by mild but progressive skeletal and cardiac myopathy. Clinical features include muscle weakness and atrophy, fl exion deformities of the elbows, and mild pectus excavatum. 38, 39 The disease often presents during childhood with muscle weakness that initially involves the lower extremities and leads to waddling gait and lumbar lordosis. Subsequently, as the disease progresses, muscles of the upper extremities and shoulders are involved. The musculoskeletal manifestations of EDMD are largely benign, with most subjects remaining functionally active to their fi fth or sixth decade.
Cardiac Involvement
Cardiac involvement is common and the most serious clinical manifestation of EDMD. Cardiac phenotypes could be categorized as conduction abnormalities, arrhythmias, and cardiomyopathy. Specifi c fi ndings comprise DCM; brady-and tachyarrhythmias, particularly supraventricular arrhythmias; conduction defects; atrial standstill; and SCD. [40] [41] [42] [43] [44] [45] First-degree AV block typically presents in the second decade of life ( Fig. 112 .5) and could progress to complete heart block and atrial standstill with ensuing junctional or ventricular escape rhythms. 39, 42, 43 Permanent atrial paralysis, otherwise a rare cardiac fi nding, is frequently seen in EDMD. 45 Ventricular tachyarrhythmias have been reported in young patients and may be responsible for the high incidence of SCD in EDMD. Because arrhythmias tend to be more severe during periods of sleep, 24-hour Holter monitoring is indicated at least annually. Permanent pacemaker implantation is indicated in symptomatic patients and could be considered in asymptomatic patients with signifi cant conduction abnormalities or bradycardia, as a prophylaxis against fatal bradyarrhythmias. 39, 42, 43 Thromboembolism, as a consequence of atrial arrhythmias, is common, and anticoagulation to prevent stroke and other thromboembolic complications is warranted. 45 A rapidly progressive DCM could occur with pronounced mitral and tricuspid valve regurgitations ( Fig. 112.6 ). Standard treatment with afterload reduction and diuretics is effective. Cardiac transplantation has been successfully performed in patients with severe cardiomyopathy. 46 Female carriers also may exhibit cardiac involvement that usually is mild. The phenotype is characterized by a late-onset mild conduction disturbance, including fi rstdegree AV block, wandering pacemaker, and intermittent sinus bradycardia. However, rare cases of sudden cardiac death in female carriers also have been documented. 47 Early detection of conduction defects and implantation of permanent pacemakers could afford an excellent life expectancy to the affected individuals. Treatment of supraventricular tachyarrhythmias and cardiomyopathies are pursued per conventional approach. prises a polymorphic repeat structure of 3.3 kilobases (kb) repeated elements referred to as D4Z4. The causal mutation is the deletion of D4Z4 repeats, which generates a smaller fragment than the anticipated normal size of 50 to 300 kb. 48, 49 Deletion of the repeat domains in D4Z4 is associated with global mis-expression (over-and underexpression) of a variety of genes. 50 
Clinical Manifestations
Facioscapulohumeral muscular dystrophy, also known as Landouzy-Dejerine disease, is characterized by involvement of muscles of the face, the scapulae, and the upper extremities. Muscular involvement is asymmetric, and bulbar extraocular and respiratory muscles are spared. It is the third most common genetic skeletal myopathy after Duchenne muscular dystrophy and myotonic muscular dystrophy, with an incidence of 1 in 20,000 with almost complete penetrance. 50 The clinical manifestation of the disease is quite variable, ranging from a very mild form of myopathy appearing late in life to that of a severe myopathy manifesting in infancy. In general, the clinical manifestations may begin during the fi rst two decades of life and commonly present as weakness and atrophy of the proximal shoulder and facial muscles with slow progression. Winging of the scapulae and loose, protruding lips are the noticeable features of the disease (Fig. 112.7) . Pseudohypertrophy is not common. In advanced stage of the disease, foot dorsifl exors and the hip girdles are also involved.
Cardiac Involvement
Cardiac involvement is not common and is often limited to the conduction system involving the SA and AV nodes and intraatrial conduction. 20, 38 Ventricular myocardium is spared. The most common cardiac fi nding is P-wave abnormalities on ECG that are present in the majority of the patients. Atrioventricular nodal and intranodal conduction delays are present in approximately one third of the patients, and easily inducible atrial fl utter and fi brillation are found in most patients. 20 Death from cardiac disease is not common. Treatment of cardiac abnormalities is directed toward specifi c conduction defects and arrhythmias as indicated.
Limb-Girdle Muscular Dystrophy (OMIM Numbers 253600, 159000, 253601, 603009, 253700, 608896, 608099, 600119, 604286, 600900, 601287, 601411, 601954, 604488, 254110, 602290, 607155, 606596, 608807, 188840)
Phenotypic Defi nition
Limb-girdle muscular dystrophy (LGMD) is a group of heterogeneous muscular dystrophies characterized by proximal muscle weakness, initially in the hip-girdle region, then in the shoulder-girdle region, and fi nally in distal muscles. 51 
Molecular Genetics
Limb-girdle muscular dystrophy is a genetically heterogeneous disease caused by at least 12 different genes, as partially listed in Facioscapulohumeral Muscular Dystrophy (OMIM Number 158900)
Phenotypic Defi nition
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder characterized by asymmetric involvement of the facial muscle, the scapulae, and the upper extremities. 48 
Molecular Genetics
Facioscapulohumeral muscular dystrophy is an autosomal dominant disease mapped to the 4q35 locus. The locus com-encoding the dystrophin glycoprotein complex are important determinants of LGMD. 51, 52 The classic autosomal dominant LGMD1A is caused by mutation in the gene encoding myotilin (TTID) 53 and a rare form of autosomal dominant LGMD by mutations in caveolin 3 (CAV3). 20 The classic autosomal recessive LGMD (LGMD2A) is caused by mutations in calpain-3 (CAPN3). 54 
Clinical Manifestations
The phenotypic expression of LGMD is quite variable. 51 The recessive form of the disease, which is the most common form, is characterized by onset of the pelvic myopathy usually in early childhood or middle age and gradual spread from the lower limbs to the upper extremities. Over the next couple of decades, severe disability could result because of the inability to walk. Death usually occurs in middle age.
The autosomal dominant form of LGMD is rare. Several families have been described in whom the family members exhibit variable clinical phenotypes with the predominant manifestations of proximal myopathy of the lower extremities.
Cardiac Involvement
Cardiac involvement is uncommon and manifests as conduction defects, including complete heart block and DCM.
Trinucleotide Repeat Syndromes
Trinucleotide repeat syndromes are a group of genetic disorders caused by expansion of naturally occurring guanine and cytosine-rich triplet repeats in genes. 55 The group comprises more than 10 different diseases including myotonic dystrophy (DM) and several neurodegenerative disorders, such as Huntington's disease and fragile site syndromes. 55, 56 Cardiac involvement is common and is a major determinant of morbidity and mortality in some of the triplet repeat syndromes, such as DM. 56, 57 Myotonic Dystrophy (OMIM Numbers 160900, 602668)
Phenotypic Defi nition
Myotonic dystrophy (Steinert's disease) is a multisystem disorder characterized by muscular dystrophy, myotonia, cataracts, hypogonadism, frontal balding, and ECG abnormalities. 58, 59 Molecular Genetics Classic DM is the prototypic trinucleotide repeats syndrome caused by the expansion of CTG (CUG) repeats in the 3′ untranslated region of dystrophia myotonica protein kinase gene (DMPK), located on chromosome 19q13.2-13.3. 60 The number of CTG repeats in normal individuals varies between 5 and 30, while it expands to more than 50 repeats and sometimes to more than several thousands in the severely affected patients with DM. An interesting feature of this disease is expansion of the size of the CTG repeats in successive generations, which is referred to as the anticipation phenomenon. 59 The severity of the clinical phenotype also increases in successive generations in conjunction with the expansion in the number of trinucleotide repeats. 59 Myotonic muscular dystrophy type 2 is a rare autosomal dominant disease characterized by myotonia of the proximal muscles and hence is sometimes referred to as proximal myotonic myopathy (PROMM). 59 The genetic basis of DM type 2 entails expansion of CCTG tetranucleotide repeats in intron 1 of the ZNF9 gene. The number of repeats could expand from the normal number of 75 repeats to more than several thousand.
The molecular mechanisms responsible for the diversity of clinical manifestations of DM are largely unknown. Unstable transcription of mRNA of the causal gene, dysregulation of transcription of the genes within the vicinity of the causal genes, and dysregulation of splicing of the target genes have been implicated in the pathogenesis of diverse phenotypes of DM. 59 
Clinical Manifestations
Myotonic muscular dystrophy is the most common inherited form of muscular dystrophy affecting adults, with an estimated prevalence of approximately 1 : 8,000 in the North American population. 59, 61 It commonly manifests as progressive degeneration of muscles, weakness, and myotonia that typically starts from the distal muscles and progresses toward the proximal muscles. Other important features of DM include cardiomyopathy, conduction defects, male pattern baldness, infertility, premature cataracts, mental retardation, and endocrine abnormalities. 59, 61, 62 The clinical manifestations are dominated by myotonia, which is a delay of muscle relaxation after contraction and is most evident after a handshake with an affected individual. An early feature is weakness of the neck fl exors and atrophy of the masseter, temporal, and sternocleidomastoid muscles (Fig. 112.8) . Consequently, patients have a weak cough refl ex and poor coordination of pharyngeal muscles and thus are prone to aspiration. Systemic manifestations include premature frontal baldness, cataracts, atrophy of the gonads, and, less commonly, gastrointestinal disorders involving the muscles of the esophagus and the colon, gastrointestinal hypermotility, hypersomnia, hearing defi cits, insulin resistance, and ptosis. 58, 59 Myotonic muscular dystrophy type 2 exhibits variable clinical manifestations, often presenting with mild myotonia and muscle weakness in the third and fourth decades of life or even later. It is a multiorgan disease involving skeletal and cardiac muscles, predominantly involving the proximal muscles and sparing facial muscles but involving the lens. It is a much milder disease than the classic DM. Muscle biopsy shows hypertrophy of type 2 fi bers and mild nonspecifi c myopathy.
Cardiac Involvement
Cardiac involvement is common and primarily manifests as cardiac conduction abnormalities and less frequently as cardiomyopathy. 61, [63] [64] [65] [66] [67] Cardiac hypertrophy and dilatation are the most common phenotypes of myocardial involvement in DM. 65 A phenotype similar to HCM has been observed occasionally. The most common cardiac fi nding is an abnormal electrocardiogram, which is noted in approximately two thirds of patients and in virtually all patients with clinically severe disease. 61, [66] [67] [68] The most common electrocardiographic abnormalities are prolongation of the PR interval, left anterior fascicular block, and prolongation of the QRS interval 61, [66] [67] [68] (Fig. 112.9 ). These fi ndings are often associated with sinus bradycardia, which is in contrast to the sinus tachycardia noted in Duchenne muscular dystrophy and Friedreich ataxia. The rate of progression of conduction abnormalities is usually slow but variable, occasionally showing rapid progression to advanced heart block. 66, 67 Other ECG fi ndings include premature atrial contractions, atrial fi brillation, and atrial fl utter, which are present in approximately 25% of the patients. 66 First-degree AV block and left anterior fascicular block are most common in patients with mild-to-moderate disease, while atrial fi brillation and fl utter are most common in patients with more severe disease. Ventricular conduction defects, such as bundle branch blocks and abnormal axis, are less common. Sudden cardiac death could occur and is believed to be due to either high-grade AV block or ventricular tachycardia. Heart failure is usually a late manifestation of DM, and overt heart failure is uncommon. 66 However, subclinical left ventricular systolic dysfunction has been reported in a signifi cant number of the cases. 69 In addition, regional wall motion abnormalities such as apical akinesis have been observed in a signifi cant number of patients. Electrocardiographic fi ndings of myocardial infarction are occasionally detected and are referred to as pseudoinfarction, because of normal-looking coronary arteries. The pseudoinfarction pattern may refl ect areas of patchy myocardial fi brosis or possibly coronary microvascular abnormalities, which have been reported in conjunction with myocardial perfusion defects. 66 Mitral valve prolapse with an audible midsystolic click has been reported in approximately one third of patients. 61 Cardiac manifestations of DM type 2 are largely similar to the classic DM, including conduction defects and less frequently cardiomyopathy.
Pathologic fi ndings include atrophy and hypertrophy of muscle fi bers, fi brosis, and fatty infi ltration of the sinus node, AV node, His bundle, and bundle branches. Cardiac muscle involvement varies from nonexistent to areas of focal or diffuse fi brosis or fatty infi ltration and ultimately advanced cardiomyopathy.
Treatment consists of specifi c therapy for arrhythmias and CHF. Advanced heart block can progress to fatal StokesAdams attacks unless a pacemaker is inserted. Mitral valve prolapse requires endocarditic prophylaxis.
Friedreich Ataxia (OMIM Number 229300)
Phenotypic Defi nition
Friedreich ataxia (FRDA) is a multisystem disorder that primarily involves the spinocerebellar tracts, dorsal columns, and pyramidal tracts. The cerebellum, medulla, heart, and endocrine system are involved less frequently. 44, 56 
Molecular Genetics
Friedreich ataxia is an autosomal recessive spinocerebellar degenerative disorder, initially mapped to chromosome 9, and is caused by expansion of the GAA trinucleotide repeats in intron 1 of FRDA. 44, 70, 71 Expansion of GAA repeats account for 97% of the cases of FRDA and point mutations for a very small minority. The encoded protein is frataxin, which is a soluble mitochondrial protein with 210 amino acids. 71 
Clinical Manifestations
The characteristics clinical fi ndings of FRDA are hypoactive deep tendon refl exes and physical signs of cerebellar dysfunction that usually start around puberty. 44 Neurologic manifestations are due to degeneration of the spinocerebellar tracts, dorsal columns, and corticospinal tracts, and include poor coordination of limb and trunk movements, diminished or absent deep tendon refl exes, Babinski sign, and impairment of proprioception. Other clinical fi ndings include dysarthria, nystagmus, pes cavus, and hammer toe. Kyphoscoliosis develops within a few years of onset and, coupled with weakness of the respiratory muscles, often leads to pulmonary insuffi ciency and infections. Cardiac involvement is common and present in almost all patients in the advanced stages of the disease. 72 Many patients succumb to CHF or arrhythmias in middle age, but some patients have a normal life span. 73 
Cardiac Involvement
Cardiac involvement has been found in 50% of patients in the early stages of the disease and is present in all cases in advances stages of the disease. 72, 73 Electrocardiograph abnormalities are present in almost all patients. In a study of 75 cases with FRDA, the most common fi ndings were ST-T wave abnormalities in 79%, right axis deviation in 40%, short PR interval in 24%, abnormal R wave in lead V 1 in 20%, abnormal inferolateral Q waves in 14%, and left ventricular hypertrophy (voltage and repolarization criteria) in 16% of cases. 72 Atrial fi brillation, atrial fl utter, supraventricular tachycardia, premature ventricular beats, and ventricular tachycardia are observed less frequently and often indicate left ventricular dysfunction.
Cardiac involvement in FRDA could manifest as either a dilated or a hypertrophic heart. Concentric left ventricular hypertrophy is the most common echocardiographic fi nding, being present in 10% to 15% of the cases, and often mimicking HCM, although asymmetric septal hypertrophy and outfl ow tract obstructions are uncommon. 72 Myocyte disarray, the histologic hallmark of HCM, is absent in patients with FRDA. A less common phenotype is global hypokinesis, with either normal or increased left ventricular internal dimensions. These patients usually have signs and symptoms of CHF and experience atrial fi brillation or fl utter or supraventricular tachycardia. Patients with DCM usually experience a progressive deterioration of cardiac function, often dying of CHF, arrhythmias, or pulmonary infections. In addition, progression from a hypertrophic to a dilated phenotype is also not uncommon. 73 Overall, the severity of clinical manifestations of FRDA correlates with the size of the repeats. 74 Cardiac histologic changes are notable for diffuse interstitial fi brosis, myocyte hypertrophy, and necrosis. 
Glycogen Storage Disorders or Glycogenosis
Glycogen storage disorder (GSD) comprises at least 12 types (0 to XI) of abnormalities that regulate glycogen synthesis and degradation. 4 Since glycogen is primarily stored in the liver and muscle, the phenotype is characterized by hypoglycemia and myopathy. Cardiac involvement is a signifi cant clinical phenotype in GSD type II (Pompe disease), type III (Forbes disease), type IV (Andersen disease), type V (McArdle disease), IIb (Danon disease), and GSD due to adenosine monophosphate (AMP)-activated protein kinase (AMPK) γ 2 -subunit mutations, all of which are discussed briefl y.
Glycogen Storage Disorder II (Pompe Disease) (OMIM Number 232300)
The prototype of GSD with predominant cardiac involvement is GSD type II or Pompe disease, an autosomal recessive disorder caused by the defi ciency of α-1,4-glucosidase (acid maltase). 75 The defi ciency results in storage of glycogen in lysosomal membranes in the liver and muscles. Only GSD II is considered a lysosomal storage disorder.
Glycogen storage disorder II is one of the most common lysosomal storage diseases, with a frequency of approximately 1 in 40,000 births. 76 The disease was fi rst described in 1932 by the Dutch physician J.C. Pompe and was shown subsequently to result from the defi ciency of the enzyme acid α-1,4-glucosidase (GAA). 77 Over 100 mutations in GAA have been identifi ed in patients with Pompe disease, which are cataloged by the Erasmus University Medical Center in Rotterdam (http://www.eur.nl/FGG/CH1/pompe/). The clinical manifestations of GSD II are remarkable for the skeletal and cardiac myopathy, which are the predominant phenotype in GSD II. Cardiac involvement is expressed as cardiac hypertrophy (HCM phenocopy), heart failure, conduction defects, and muscle involvement as muscular hypotonia. 78 Heart failure due to Pompe disease commonly presents within the fi rst year of life as massive cardiomegaly with severe heart failure. The typical ECG fi ndings are short PR interval and very high QRS voltages. The severity and progression of the disease is primarily determined by the residual activity of acid α-1,4-glucosidase. Those with severe defi ciency or the complete lack of the enzyme die within the fi rst decade of life, while those with a mild defi ciency may have a normal life span. High protein diet and recombinant acid α-glucosidase have been used effectively for treatment of this disorder. 79 Glycogen Storage Disorder III (Forbes Disease) (OMIM Number 232400) Forbes disease is caused by mutations in the GDE gene, encoding the glycogen debrancher enzyme, a large monomeric protein with a molecular weight of 160,000 to 170,000. 80 Liver is the primary organ involved, followed by skeletal muscle and to a lesser extent cardiac muscle. Cardiac involvement manifests with hypertrophy, sometimes mimicking HCM, and less often DCM and heart failure. 81 Glycogen Storage Disorder IV (Andersen Disease) (OMIM Number 232500)
Glycogen storage disorder IV is a rare autosomal recessive disorder with heterogeneous clinical manifestations, primarily restricted to the liver and neuromuscular system. 82 The typical form is characterized by progressive and lethal liver cirrhosis. Neuromuscular involvement is less common but could present in utero or very early in life, often with a lethal outcome. Cardiac involvement, which could occur in isolation without involvement of the liver, or in conjunction with skeletal myopathy, includes cardiac hypertrophy and failure. 82 The causal gene is GBE, which is located on 3p12 and encodes the 702-amino-acid branching enzyme. 83 Mutations in GBE inactivate glycogen branching enzyme activity, leading to cirrhosis and other manifestations of this storage disease.
Glycogen Storage Disorder V (McArdle Disease) (OMIM Number 232600)
McArdle disease is a rare disorder caused by mutation in the gene encoding muscle glycogen phosphorylase (PYGM). 84 The clinical manifestations of McArdle disease is variable and comprises muscle weakness, myalgia, exercise intolerance, and muscle cramps that usually begin in childhood and young adulthood. 85 The disease follows a slowly progressive but usually benign and mild myopathy, interspersed with occasional transient myoglobinuria due to rhabdomyolysis after exercise. Cardiac involvement is uncommon and manifests as cardiac hypertrophy, which may progress to dilatation and failure.
Glycogen Storage Disorder IIb (Danon Disease, Antopol Disease) (OMIM Number 300257)
Danon disease is an X-linked dominant myopathy caused by mutations in lysosomal-associated membrane protein-2 (LAMP2). 86 The clinical manifestations of Danon disease include proximal muscle weakness, HCM more commonly and DCM less commonly; conduction defect; ventricular preexcitation (Wolff-Parkinson-White syndrome, WPW); supraventricular arrhythmias; mental retardation; and hepatomegaly. [86] [87] [88] Glycogen Storage Disorder Due to AMPK-γ 2 -Subunit Mutations Molecular genetic studies of families with the clinical phenotype of HCM and WPW syndrome led to chromosomal mapping to the 7q3 locus, 89 and subsequent identifi cation of the causal gene as PRKAG2, which encodes the γ2 regulatory subunit of AMPK. [90] [91] [92] AMPK is a heterotrimeric metabolic stress-sensing protein kinase, composed of a catalytic α subunit, a noncatalytic β subunit, and a noncatalytic γ subunit. Mutations in the γ 2 subunit result in accumulation of glycogen in cardiac myocytes and the conduction system. The phenotype is predominantly restricted to the heart and is characterized by cardiac hypertrophy, mimicking HCM; preexcitation, mimicking WPW syndrome; and AV conduction defects. 90, 92, 93 There is considerable variability in the phenotypic expression, with predilection toward pronounced hypertrophy in some and severe conduction defects in others. The clinical presentation of the affected individuals is refl ective of the underlying pathology and varies from symptoms of dyspnea and chest pain to symptoms of palpitations and syncope. 90, 92, 93 Both the hypertrophic phenotype and the AV conduction defects are progressive, and permanent pacemaker implantation is required in a considerable number of patients. 93 In a study of 44 individuals with AMPK mutations and a mean age of 24 years, the 12 year survival rate was 91%.
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Lysosomal Storage Diseases
Lysosomal storage diseases are characterized by accumulation of nonmetabolized substrates inside the lysosomes, which result from a defi ciency or defect in one of the approximately 40 lysosomal enzymes involved in the metabolism of glycogen (GSD II), lipid, glycoprotein, and mucopolysaccharide. 1 The phenotype is characterized by multiorgan involvement due to deposit of nonmetabolized substrates. Table  112 .1 is a partial list of storage disorders with predominant cardiac involvement and their causal genes. Several of the disorders are discussed briefl y.
Sphingolipidoses
Sphingolipidoses are a subgroup of lysosomal storage disorders characterized by accumulation of sphingomyelin in reticuloendothelial due to genetic defects in the catabolism of sphingosine-containing lipids. 94 Examples of sphingolipidosis include Fabry disease, Gaucher disease, and NiemannPick disease.
Fabry Disease (OMIM Number 301500)
Fabry disease is an autosomal recessive lysosomal storage disease characterized by the defi cient activity of α-galactosidase A (α-Gal A), also known as ceramide trihexosidase, which results in the deposits of glycosphingolipids in multiple organs. 95 It is caused by mutations in the GLA gene on chromosome Xq22, encoding the 429-amino-acid lysosomal hydrolase α-Gal A protein. 95 The estimated prevalence of the disease is 1 : 40,000 to 1 : 60,000 male newborns. 96 The phenotype is characterized by skin lesions referred to as angiokeratoma, renal insuffi ciency, proteinuria, neuropathy, transient ischemic attack, stroke, anemia, corneal deposits, and HCM phenocopy. 95 Often the phenotype of cardiac hypertrophy observed in Fabry disease could be indistinguishable from the true HCM caused by mutations in sarcomeric proteins (Fig. 112.10) . 97, 98 Other cardiac manifestations could include high QRS voltage; conduction defects; cardiac arrhythmias; valvular regurgitation, particularly mitral regurgitation; coronary artery disease; myocardial infarction; and aortic annular dilatation (Fig. 112.11 ). The severity of the disease including the age of onset of symptoms inversely correlates with the residual activity of the mutant enzyme. Those with severe defi ciency express a severe disease very early in life, which often leads to death in the second and third decades of life. 96 Although the disease predominantly affects males, female carriers may exhibit a milder form of the disease because of inactivation of the Xchromosome. 98 The diagnosis is based on measurement of α-Gal A levels and activity in leukocytes in the affected individuals. Enzyme replacement therapy with gene-activated human α-Gal A (agalsidase α) or recombinant human α-Gal A (agalsidase β) has been successfully applied for the treatment of Fabry disease. [99] [100] [101] [102] Phase I and II clinical studies have established the safety of administration of the recombinant α-Gal A, and phase III clinical trials have established the effi cacy of enzyme replacement therapy in normalization of myocardial and vascular histology. 100 Thus, the current therapy of patients with Fabry disease should include considerations for enzyme replacement therapy.
Gaucher Disease (OMIM Number 230800)
Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene, encoding acid-β-glucosidase or glucocerebrosidase. 2, 103 The clinical manifestations of Gaucher disease are diverse and in the type I form include skin lesions, hematologic abnormalities, hypersplenism, and bone lesions. Atypical manifestations include parkinsonism, myoclonic epilepsy, and collodion skin. 103 Cardiac involvement includes calcifi cations of the pericardium, aorta, coronary ostium, and valves, leading to a variety of cardiac pathology and ultimately heart failure. 104 
Mucopolysaccharidoses
Mucopolysaccharidoses (MPS) are a heterogeneous group of genetic disorders caused by mutations in lysosomal enzymes involved in the degradation of glycosaminoglycans or mucopolysaccharides. 105 Cardiac involvement in MPS is primarily restricted to cardiac hypertrophy and valvular disorders. Hurler syndrome, Scheie syndrome, and Hurler-Scheie syndrome are phenotypic variants representing the severe, mild, and intermediary forms of the disease, respectively. The phenotype is caused by mutations in IDUA, which encodes the α-L-iduronidase. 106 The clinical manifestations of this rare disorder are organomegaly, including cardiac enlargement; mental retardation; coarse facies; hernias; and corneal cloudiness. The disease often manifests during the fi rst decade of life and leads to early death, in the fi rst and second decades of life. Cardiac involvement is common and comprises cardiac hypertrophy, cardiac dilatation, endocardial fi broelastosis, thickening of the intima of coronary arteries, and thickening and regurgitation of the mitral and aortic valves. 107, 108 Enzyme replacement therapy with recombinant human α-L-iduronidase has been shown to be safe and somewhat effective in attenuating systemic signs and symptoms in patients with Hurler syndrome. 109 In addition, hematopoietic stem-cell transplantation has been successfully used in treatment of patients with Hurler syndrome and is considered the treatment of choice for affected children younger than 2 years of age without or with minimal central nervous system involvement. 110 Mucopolysaccharidoses Type II: Hunter Syndrome (OMIM Number 309900)
Hunter syndrome is an X-linked disorder caused by mutations in the IDS gene, which codes for iduronate sulfatase. 111 The defi ciency of iduronate sulfatase results in aggregation and tissue deposits of dermatan and heparin sulfate. The clinical features include mental retardation, "gargoyle" face, loss of hearing, gastrointestinal and respiratory symptoms, and skeletal myopathy. The heart is involved in the majority of the patients with Hunter syndrome. A variety of cardiac pathology has been reported, including thickening and regurgitation of mitral and aortic valves, myocardial thickening, conduction disturbances, arrhythmias, coronary arterial narrowing, myocardial infarction, pulmonary hypertension, congestive cardiac failure, left ventricular aneurysms, and sudden cardiac death. Primary myoadenylate deaminase defi ciency is a relatively common disease with a prevalence of up to 2% in the general population. 113 Its clinical manifestations range from an asymptomatic course to that of muscle cramps, stiffness, weakness, and myalgia occurring in early childhood. 113 The genetic basis of this disease has been elucidated as being mutations in the AMPDI gene. 114 The most common mutation is homozygous 34C > T transition in exon 2, which by changing the codon from CAA to stop codon TAA results in premature truncation of the protein and hence defective enzymatic activity. Thus, the mutation could result in increased levels of adenosine in the tissues (Fig. 112.12) . While the homozygous 34C > T mutation accounts for the majority of the myoadenylate deaminase defi ciency, additional mutations in AMPD1 also have been detected. [114] [115] [116] Cardiac manifestations of myoadenylate deaminase deficiency include DCM, heart failure, and electrocardiographic abnormalities (Figs. 112.13 and 112.14). Heterozygosity for the 34C > T mutation in AMPD1 is relatively common in the general population and does not impart a discernible muscle phenotype. 113 Recent studies have suggested a protective role for the heterozygous 34C > T mutation in patients with heart failure and coronary artery disease. 117, 118 Carnitine Defi ciency (OMIM Number 212140) Systemic carnitine defi ciency could arise from inadequate dietary intake or defective synthesis, uptake, and transport, or decreased tubular reabsoption of carnitine. 2 Carnitine is necessary for the entry of long-chain fatty acids into mitochondria for β-oxidation, a multistep process involving several enzymes including carnitine transporter, carnitine palmitotransferase I (CPTI) and II (CPTII), and translocase ( Fig. 112.15 ). Defi ciency of any of these enzymes could lead to defective β-oxidation of fatty acids and metabolic myopathy that typically involves the heart and manifests as DCM and heart failure. Mutations in any of the genes encoding the above enzymes could cause systemic carnitine defi ciency. Mutations in the chromosomal gene encoding solute carrier family 22, member 5 (SLC22A5) known as sodium iondependent carnitine transporter OCTN2, lead to autosomal recessive systemic carnitine defi ciency. 119 Similarly, carnitine defi ciency could result from mutations in CPTI and CPTII. 120, 121 CPTI defi ciency is an autosomal recessive disease characterized by severe episodes of hypoketotic hypoglycemia that usually occur in infancy or childhood and is precipitated by fasting or an illness. 120 Defi ciency of CPTII, which catalyzes the last step in entry of activated long-chain fatty acids into mitochondria for β-oxidation, is the most common inherited disorder of mitochondrial long-chain fatty acid oxidation. 122 While the phenotypic expression of systemic carnitine defi ciency is variable, the genetic forms usually manifest as progressive DCM with heart failure, skeletal myopathy, hypoglycemia, and hyperammonemia. 2, 122 The phenotypic expression also includes recurrent episodes of rhabdomyolysis, often triggered by heavy exercise, fasting, or a febrile illness; hypoglycemia with an inadequate ketotic response; and abnormalities of the central nervous system and liver. Defi ciency of short, medium, long, and very long chain acylcoenzyme A (CoA) dehydrogenases (ACAD) by impairing mitochondrial fatty acid oxidation could result in intermittent hypoglycemia, lethargy, peripheral lobular fatty infi ltration of liver, and cardiac hypertrophy and failure. 2, 123 Other clinical features include fasting hypoglycemia with inadequate ketotic response, hepatic dysfunction, skeletal myopathy, metabolic acidosis, failure to thrive, developmental delay, seizures, and sudden death. 123 Nonketotic hypoglycemia is a feature of medium-chain and long-chain ACAD defi ciency but not short-chain ACAD defi ciency. The majority of medium-chain acyl-CoA dehydrogenase defi ciency is caused by the mutation in ACADM that leads to substitution of glutamic acid for lysine at position 329 in the mutant protein. 124 In contrast, the molecular genetic basis of short-chain acyl-CoA dehydrogenase defi ciency is more heterogeneous. 125 Refsum Disease (OMIM Number 266500)
Refsum disease is an autosomal recessive disorder due to defective enzymatic activity of phytanoyl-CoA hydroxylase, which results in accumulation of phytanic acid, an unusual branched-chain fatty acid, in tissues and body fl uids. 126 Mutations in two genes, namely PAHX (also known as PHYH) and PEX7, which encode phytanoyl-CoA hydroxylase and the PTS2 receptor or peroxin-7, respectively, have been identifi ed in patients with Refsum disease. [127] [128] [129] Refsum disease is clinically characterized by a tetrad of retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and elevated protein levels in the cerebrospinal fl uid. Electrocardiographic abnormalities are common, but cardiac hypertrophy and heart failure are uncommon. 126, 130 Mitochondrial Myopathies (Mitochondrial DNA Mutations)
Mitochondrial DNA (mtDNA) is a circular double-stranded genome of approximately 16.5 kb. Mitochondrial DNA encodes 13 polypeptides of the respiratory chain complexes I, III, IV, and V subunits; 28 ribosomal RNAs; and 22 transfer RNAs (tRNAs). 131 Each mitochondrion has multiple copies of mtDNA and each cell contains hundreds to thousands of mitochondria. Spontaneous mutations do occur during mitochondrial replication and lead to a signifi cant degree of heteroplasmy, which increases over time as the mitochondria multiply. In general, a single mutation that affects 80% to 90% of the total mtDNA pool is necessary to cause significant mitochondrial functional abnormalities and a clinical phenotype. 132 Given the widespread distribution of mitochondria, mtDNA mutations involving oxidative phosphorylation pathways often result in complex phenotypes that involve multiple organs including the heart. 133 The common cardiac abnormalities are hypertrophy, dilatation, and conduction defects.
Kearns-Sayre Syndrome (OMIM Number 530000) Kearns-Sayre syndrome (KSS) is a multiorgan disease caused by sporadically occurring mutations in mtDNA. 134, 135 It is characterized by a triad of progressive external ophthalmoplegia, pigmentary degeneration of the retina, and cardiac AV blocks. 134, 136 Kearns-Sayre syndrome usually presents in late childhood or adolescence, but it has been reported from infancy to old age. The most common cardiac phenotype in KSS is conduction defects, predominantly progressive AV block (Fig. 112.16 ). The course of progression of AV block is variable. Less commonly, DCM and HCM could occur. Other features of KSS include ptosis, torticollis, sensory neural deafness, ataxia, limb weakness, sexual immaturity, short stature, mental retardation, and increased cerebrospinal fl uid protein concentration (Fig. 112.17) .
The pathologic features of KSS include ragged red fi bers on Gomori trichrome staining, which represent peripheral and intermyofi brillary accumulation of abnormal mitochondria (Fig. 112.18) ; proliferation of abnormal mitochondria in cardiac tissue; and extensive changes in the distal portions of the His bundle and proximal bundle branches. 137 Degenerative myocardial changes have also been noted but are less common than those of skeletal muscles and the conduction system.
Prophylactic permanent pacemaker implantation could prevent the risk of sudden cardiac death, which is usually due to complete heart block in the affected individuals. 
Sarcomeric Myopathies
Nemaline Myopathies (OMIM Numbers 609284, 256030, 609285, 190990, 605355, 609273) Nemaline myopathy comprises a heterogeneous group of congenital myopathies characterized by the presence of abnormal thread-or rod-like structures in muscle fi bers, referred to as nemaline bodies (Fig. 112.19) . 138 Clinically, nemaline myopathies are characterized by diffuse muscle weakness and hypotonia that predominantly involve the proximal muscles including facial, bulbar, and respiratory muscles. 139 The most severely affected muscles are those of the limb girdle and trunk. The phenotype usually manifests at birth or in early infancy, but the age of onset and the severity of the disease exhibit signifi cant variability. Nemaline rods are found not only in skeletal muscle but also occasionally in cardiac muscle and the conduction system, which could lead to arrhythmias and cardiac dysfunction. Overall, cardiac involvement is uncommon and often presents with HCM, DCM, and heart failure. 138, 140 Autosomal dominant and autosomal recessive forms of nemaline myopathy have been described. Molecular genetic studies have led to identifi cation of mutations in several genes, including TPM3, 141 NEB, 142 TPM2, 143 TNNT1, 144 and ACTA1, 145 encoding α-tropomyosin, nebulin, β-tropomyosin, slow skeletal muscle troponin (troponin T1), and skeletal muscle α-actin (actin 1), respectively.
Desminopathies or Myofi brillar Myopathies (OMIM Numbers 601419, 609200, 608810, 602771) Desmin-related myopathies (DRMs), also known as myofibrillar myopathies, are a clinically and genetically heterogeneous group of familial or sporadic muscular disorders characterized by abnormal intrasarcoplasmic aggregates of desmin, the intermediary fi laments of muscles. In addition to desmin, the intrasarcoplasmic aggregates also contain cytoskeletal proteins dystrophin, vimentin, nestin, and β-spectrin; sarcomeric proteins titin, nebulin, actin, and α-actinin; nuclear proteins emerin and laminB; chaperon proteins ubiquitin and α/B crystalline; Alzheimer-type proteins amyloid precursor protein and β-amyloid epitopes; cyclin-dependent kinases CDK2, CDK4, and CDK7; and others. 138, 146 The clinical manifestations of DRM include skeletal muscle weakness, cardiac conduction blocks, arrhythmias, restrictive heart failure, DCM, HCM (phenocopy), lens opacities, and respiratory failure. 147 Both autosomal dominant and recessive forms of DRM have been described, and mutations in desmin (DES), 148, 149 myotilin (TTID), 150 α/B crystallin (CRYAB), 151 and selenoprotein N (SEPN1) 152 have been identifi ed. Mutations in TTID are also known to cause LGMD, as discussed earlier. 53 There are differences in the phenotypic expression of DRM caused by mutations in the above genes. For example, DRM due to mutations in α/B crystallin is associated with cataract, and those caused by mutations in selenoprotein are also referred to as rigid-spine muscular dystrophy 1. 153, 154 In addition, mutations in DES have been found in patients with DCM in the absence of skeletal myopathy. Myotubular myopathy comprises a heterogeneous group of congenital myopathies, characterized pathologically by a large portion of hypotrophic muscle fi bers, with central (as opposed to peripheral) nuclei and other changes resembling fetal myotubes. 156 The clinical manifestations are variable but notable for severe generalized hypotonia and severe respiratory diffi culty at birth, often observed in the autosomal recessive form. In contrast, the autosomal dominant form often manifests as a late-onset and slowly progressive myopathy. Nonetheless, there is considerable overlap in the phenotype expression of autosomal dominant and recessive myotubular myopathies. 156, 157 In addition, X-linked myotubular myopathy also has been described. Cardiac involvement is uncommon and comprises myocardial fi brosis, conduction defect, DCM, and heart failure. 158 The cause genes for the autosomal form are unknown and the X-linked form is myotubularin (MTM1), which has been mapped to Xq28. 159 Over 250 different mutations in MTM1 have been described, the vast majority of which are nonsense or insertion/deletion mutations, and missense mutation account for approximately one third of all mutations. 160, 161 Genotype-phenotype correlation studies suggest truncation mutations lead to a severe form of X-linked myotubular myopathy and early lethality, while some missense mutations are associated with milder forms and prolonged survival. 161 The pathogenesis of myotubular myopathy entails reduced expression of myotubulin leading to immature myotubes.
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Others
Barth Syndrome (OMIM Number 302060)
Barth syndrome is an X-linked disorder characterized by DCM, skeletal myopathy, neutropenia, and abnormal mitochondria. 163 Phenotypic expression of Barth syndrome is variable, ranging from presentation in early childhood with severe cardiomyopathy to that of isolated cases of neutropenia without cardiac involvement. 164 Cardiac involvement typically presents as DCM and left ventricular noncompaction syndrome and less frequently as left ventricular hypertrophy (Fig. 112.20) . [164] [165] [166] Cardiac phenotype could present on the fi rst day of life and often in early childhood but much less commonly in adulthood. 167 Occasionally, ventricular function improves over time and the disease becomes subclinical, while in others the disease could be progressive and diffi cult to treat, necessitating heart transplantation. 165 Supraventricular arrhythmias and benign or malignant ventricular could occur and could be fatal (Fig. 112.21) . 167 Skeletal weakness and myopathy, variable degree of neutropenia, and growth retardation could present in a signifi cant number of patients. 164 Mortality is the highest within the fi rst 4 years. 164 The causal gene has been identifi ed as the tafazzin (TAZ) or G4.5 gene, which encodes tafazzin, a protein that is expressed at high levels in cardiac and skeletal tissues. 168 The function of the protein is not clearly known. However, a defi ciency of cardiolipin, especially its tetralinoleoyl form (L(4)-CL), has been shown in many tissues including the myocardium in patients with Barth syndrome. 169 Cardiolipin is the principal polyglycerophospholipid in the heart and most mammalian tissues, and is present almost exclusively in the inner mitochondrial membrane. 170 Defi ciency of cardiolipin is expected to affect mitochondrial respiratory chain functions. 169, 170 Carney Complex (OMIM Numbers 160980, 605244) and Variant of Carney Complex (OMIM Number 608837)
The classic Carney complex is a multiorgan disorder characterized by spotty skin pigmentation (lentiginosis), cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas. 171 The cardiac phenotype in the Carney complex is notable for myxomas, which are present in approximately half of the cases, can be located in any or all chambers, and are often recurrent after surgical resection. 171 Carney complex has been mapped to chromosomes 17q23-q24 and 2p16. 172, 173 The causal gene in families mapped to 17q23-q24 is PRKAR1A, which encodes protein kinase A regulatory subunit 1-α. 174, 175 The causal gene in families mapped to 2p16 locus remains unknown.
The Carney complex variant (trismus-pseudocamptodactyly syndrome) is a familial hand-heart syndrome characterized by cardiac myxomas, spotty skin pigmentation, cutaneous lesions, and distal arthrogryposis, including pseudocamptodactyly of the hands and feet, and trismus. 176 The causal gene was mapped to 17p13.1 and was subsequently identifi ed as MYH8.
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Summary
Neuromuscular disorders and skeletal myopathies are a group of heterogeneous disorders with diverse and overlapping phenotypic expression. The heart is commonly involved in many neuromuscular disorders and skeletal myopathies and occasionally is the fi rst manifestation of such disorders. Cardiac involvement often presents as dilated cardiomyopathy and less commonly as hypertrophic cardiomyopathy. The latter is considered a phenocopy and often phenotypically is indistinguishable from true hypertrophic cardiomyopathy. Conduction defects are also common and often progressive, leading to permanent pacemaker implantation. It is important to note that often cardiac involvement is subclinical, and therefore routine periodic cardiac screening is recommended for all patients with neuromuscular disorders and skeletal myopathies. The signifi cance of the latter is evident from the fact that cardiac involvement heralds a poor prognosis and is the leading cause of death in many of such disorders.
Recent studies have delineated the molecular genetic basis of many neuromuscular disorders and myopathies and have provided signifi cant insight into their pathogenesis. It is expected that advances in the molecular genetics and biology of these disorders will lead to early and accurate preclinical diagnosis, independent of the clinical phenotypes; additional risk stratifi cations; and the development of specifi c therapies targeted at either replacing the defi cient enzymes or blocking the mutant proteins.
